Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB

Yusuke Muro; Takeo Kosaka; Ryuichi Mizuno; Toshio Ohashi; Naoyuki Shigematsu; Mototsugu Oya

Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB

Am J Clin Exp Urol. 2015 Apr 25;3(1):48-50. eCollection 2015.

Authors

Yusuke Muro¹, Takeo Kosaka¹, Ryuichi Mizuno¹, Toshio Ohashi², Naoyuki Shigematsu², Mototsugu Oya¹

Affiliations

¹ Department of Urology, Keio University School of Medicine Tokyo, Japan.
² Department of Radiology, Keio University School of Medicine Tokyo, Japan.

PMID: 26069888
PMCID: PMC4446383

Abstract

We report a first case of using a 5α-reductase inhibitor (5ARI) and combined androgen blockade (CAB) as a cytoreductive regimen before prostate brachytherapy. Prostate volume reduction with CAB is limited to approximately 40% in most cases, making it difficult to meet anatomical constraints to perform these procedures in cases with large prostate volume. With the added administration of 5ARI, further volume reduction can be expected. Here, we describe this cytoreductive regimen used in a 63 year-old prostate cancer patient who became eligible to receive brachytherapy after dutasteride (0.5 mg daily) was added to CAB and prostate volume reduction of 57% was achieved.

Keywords: 5α-reductase inhibitor; Combined androgen blockade (CAB); brachytherapy; dutasteride; prostate cancer; ultra-combined androgen blockade (UCAB).

Publication types

Case Reports